Citizens raised the firm’s price target on Argenx (ARGX) to $944 from $925 and keeps an Outperform rating on the shares. Argenx reported Q4 results in line with its prior preannouncement, with continued VYVGART growth driven by PFS launch momentum, and announced positive Phase 3 data in ocular myasthenia gravis, highlighting a low-risk commercial expansion opportunity including seronegative MG patients, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target lowered to $1,227 from $1,248 at Stifel
- Vyvgart’s Strengthening MG Franchise and Pipeline Catalysts Support Buy Rating on Argenx
- Argenx Posts First Operating Profit on Surging VYVGART Sales and Expanding Autoimmune Pipeline
- Argenx Reports Positive Phase 3 VYVGART Data in Ocular Myasthenia Gravis
- Argenx announces ADAPT OCULUS study met primary endpoint